Monopar Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

September 04, 2024 | Last Trade: US$4.40 0.46 11.55

WILMETTE, Ill., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that Chandler D. Robinson, MD, Monopar’s Chief Executive Officer, will present at the H.C. Wainwright 26^th Annual Global Investment Conference. The Company’s presentation will be webcast beginning on Monday, September 9, 2024 at 7:00 a.m. ET. In person one-on-one meetings will take place at the Lotte New York Palace, NY, NY from September 9 - 11, 2024.

About Monopar Therapeutics Inc.

Monopar Therapeutics is a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients, including Phase 1-stage MNPR-101-Zr for imaging advanced cancers, Phase 1-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac225 for the treatment of advanced cancers, as well as early development stage programs against solid cancers. For more information, visit: www.monopartx.com.

CONTACT:

Monopar Therapeutics Inc.
Investor Relations
Karthik Radhakrishnan
Chief Financial Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.

Follow Monopar on social media for updates:
Twitter: @MonoparTx LinkedIn: Monopar Therapeutics

Stock Quote

Last Trade:	US$4.40
Daily Change:	0.46 11.55
Daily Volume:	171,340
Market Cap:	US$15.470M

September 12, 2024 Monopar Therapeutics Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr August 21, 2024 Monopar Therapeutics Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers August 14, 2024 Monopar Therapeutics Announces Initial Data for First Patient Dosed in Radiopharma Phase 1 Clinical Trial of MNPR-101-Zr August 09, 2024 Monopar Therapeutics Reports Second Quarter 2024 Financial Results and Recent Developments July 09, 2024 Monopar Therapeutics Announces First Patient Enrolled in First-in-Human Phase 1 Trial for Its Novel Radiopharmaceutical MNPR-101-Zr LOAD MORE NEWS

Featured Stock

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE